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S U M M A R Y
Objectives: Hepatitis C virus (HCV) genotype has been described as an independent predictor of the
response to therapy. A mixed infection with two types of HCV is probably an uncommon event. The aim
of this study was to determine the occurrence of mixed infection with two different HCV genotypes in
adult patients with chronic hepatitis C eligible for treatment.
Methods: Plasma samples and clinical and demographic data were collected from 1159 patients with
hepatitis C. The INNO-LiPA HCV assay was used to identify the HCV genotypes.
Results: The dominant genotype was genotype 1, which was found to be responsible for 83.9% of
infections, with subtype 1b being the most common. A mixed genotype infection was detected in
26 patients (2.2%). The most common mixed genotype was 1a+1b detected in 17/26 patients (65%).
Antiviral therapy led to complete elimination of both genotypes in 50% of patients with 1b+3a infection
and in 33% of patients with 1b+4a infection.
Conclusions: The results obtained showed that infection with mixed HCV genotypes in Polish patients
with hepatitis C is uncommon. The selective elimination of genotypes 3a and 4a after therapy conﬁrms
the greater resistance to treatment of genotype 1b. In the context of new anti-HCV drug development,
further investigations are needed to determine the clinical importance of mixed HCV infection.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Globally, 80–185 million people are infected with the hepatitis
C virus (HCV).1 The majority of infected individuals (75–80%) are
unaware of their infection. These patients are at risk of progression
of HCV disease, leading to cirrhosis (in 20–30% of them after 10–20
years of infection), end-stage liver disease, and hepatocellular
carcinoma (HCC).2
There are seven HCV genotypes with whole-genome nucleotide
sequences differing by more than 30%.3,4 According to Robertson* Corresponding author. Tel.: +48 605 723 017; fax: +48 61 869 11 43.
E-mail address: ewego@poczta.onet.pl (E. Gowin).
http://dx.doi.org/10.1016/j.ijid.2015.12.007
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).et al., genotypes 1, 2, 4, and 5 form separate clades (1, 2, 4, and 5,
respectively), genotypes 3 and 10 form clade 3, and genotypes 6, 7,
8, 9, and 11 form clade 6.5 For the purpose of this article, the term
genotype has been used. The heterogeneity within genotypes has
resulted in 67 subtypes. Isolates from the same HCV subtype differ
in nucleotide sequence by no more than 5–15%.4,5 Because acute
HCV infection is typically asymptomatic, most genotyping is
probably conducted on individuals with chronic infection.
The frequency of the different HCV genotypes is different in
different parts of the world. Genotype 1 is the most widely
dispersed worldwide. In the USA, genotype 1 accounts for 70% of
infections and genotypes 2 and 3 account for the majority of the
remaining 30%.1 In Europe the percentage of genotype 2 and









1 61 43 18 0.0004 42
1+3a 4 0 4 0.0531 43
1a 101 51 50 0.6337 28
1a+1b 17 10 7 0.3786 47
1b 810 399 411 0.2594 43
1b+3a 2 1 1 0.96 46.5
1b+4 3 0 3 0.3342 33
2b 1 0 1 0.3342 53
3a 111 38 73 0.0019 40
4 14 7 7 0.894 43
4a/4c/4d 34 10 24 0.0181 34
4e 1 0 1 0.3342 43
Total 1159 559 600
Figure 1. The distribution of genotypes in different age groups.
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drug users. HCV genotype 4 predominates in the Middle East,
genotype 5 in South Africa, and genotype 6 in South China and
Southeast Asia. The most common genotypes in England are 1 and
3.8 The different HCV genotypes do not differ in clinical
presentation or severity of the illness.
The standard treatment for chronic hepatitis C consists of
pegylated interferon (PEG-IFN) and ribavirin (RBV). The response
rate, measured as the sustained virological response (SVR), depends
largely on the viral genotype. Many patients drop out of treatment
due to the severe side effects of interferon and the length of the
therapy. Newer agents – the direct-acting antivirals (DAAs) – raise
the prospect of virus elimination, and cure rates reach 90%.9
The important question is who should be treated for hepatitis C
and when should this treatment be performed? The World Health
Organization (WHO) recommends giving therapy to those with
advanced disease. Further work is required to determine the
response rate and to estimate the response rate and risk of
resistance for the different HCV genotypes. HCV genotype has been
described as an independent predictor of the response to therapy.
Mixed infection with two HCV genotypes is probably an
uncommon event.10 However, in some populations (e.g., persons
who inject drugs (PWID) and men who have sex with men (MSM))
mixed infections occur in 25% to 39% of patients.11,12 Revealing the
occult genotypes might be necessary for the selection of the
appropriate antiviral therapy. In the context of the newer drugs,
knowledge of the distribution of HCV genotypes may help
healthcare systems prepare the resources required to treat the
predominant genotypes in their region.
The aim of this study was to determine the occurrence of mixed
infection with two types of HCV in a cohort of adult patients with
chronic hepatitis C eligible for treatment.
2. Materials and methods
Plasma samples were collected from 1159 adult patients with
chronic hepatitis C eligible for treatment. Before genotyping, the
detection of HCV RNA was performed to conﬁrm infection. The
second-generation test INNO- LiPA HCV II (Innogenetics) for the
detection of polymorphisms in the 50 non-coding region of HCV
was used to determine the genotypes. In this procedure, the highly
conserved 59-base pair non-coding region of the HCV genome was
ampliﬁed by nested reverse transcription PCR with two sets of
universal biotinylated HCV primers. The ampliﬁed products were
then hybridized to oligonucleotide probes designed to be speciﬁc
for the different HCV types and subtypes and were immobilized as
parallel bands on nitrocellulose strips. The INNO-LiPA HCV II assay
allows the identiﬁcation of HCV genotypes 1a, 1b, 2a, 2b, 3a, and
4a, 4c, 4d, 4e, 5, or 6. Clinical and demographic data were collected
for all patients. A group of patients with mixed genotype was
followed after treatment.
Patients were divided into subgroups based on the HCV
genotypes detected. The age and sex distributions were compared
between the groups. The genotype distribution was evaluated in
relation to the age groups 18–40 years, 41–60 years, and >60 years.
3. Results
There were 1159 patients in the study group: 559 women
(48.2%) and 600 men (51.8%). All 1159 serum samples tested in this
study were HCV RNA-positive by PCR and could thus be genotyped
with the INNO-LiPA HCV II assay. For 61 patients with genotype 1 it
was not possible to distinguish between 1a and 1b; these patients
were diagnosed as having genotype 1. Female patients were
signiﬁcantly older: their mean age was 43.6 years vs. 39.9 years for
men (p = 0.0001). Details are presented in Table 1.The dominant genotype in the population studied was genotype
1, which was responsible for 83.9% (972/1159) of infections.
Subtype 1b was the most common single genotype in all age
groups and was detected in almost 70% of patients. Genotypes
5 and 6 were not detected.
3.1. Single genotypes
The comparison of patients infected with a single genotype
showed signiﬁcant age and sex differences between the groups.
The distribution of genotypes was different in the different age
groups (details are presented in Figure 1). The youngest were
patients infected with genotype 1a (mean age 28 years) and the
oldest with genotype 2b. Female patients with a single infection
were signiﬁcantly older than male patients. Genotype 3a was more
common among men (p = 0.0024), while genotype 1 was more
common among women (p = 0.0003). The difference was of
statistical signiﬁcance and was greatest in the 41–60 years age
group (details are presented in Table 2).
3.2. Mixed genotypes
A mixed genotype infection was detected in 26 patients (2.2%):
15 men (2.5%) and 11 women (1.9%). The difference was not of
statistical signiﬁcance (p = 0.5519). The mean age of these patients
was 46.9 years. The age differences among patients with particular
mixed genotype infections were not statistically signiﬁcant. The
most common mixed genotype was 1a+1b, which was detected in
17/26 patients (65%). Genotype 1a+1b was detected in 10 of
11 women with an infection caused by mixed genotype.
Table 2
Comparison of the genotype distribution by age group
18–40 years 41–60 years 60+ years
Female Male p-Value Female Male p-Value Female Male p-Value
1 18 13 0.0882 16 4 0.0035 9 1 0.2257
1a+3a 0 2 0.2156 0 2 0.2343 0 0 -
1a 39 45 0.5320 9 5 0.1578 3 0 0.4377
1a+1b 4 2 0.2457 3 4 0.9824 3 1 0.5886
1b 158 202 0.7141 176 167 0.2666 65 41 0.0624
1b+3a 0 0 - 0 0 - 1 1 0.9298
1b+4 0 1 0.3817 0 1 0.4008 0 1 0.6051
2b 0 0 - 0 1 0.4008 0 0 -
3a 18 38 0.0757 16 34 0.1214 4 1 0.4904
4 3 3 0.7395 4 1 0.1509 0 3 0.3699
4a/4c/4d 0 16 0.1215 0 9 0.2308 0 0 -
4e 0 0 - 0 1 0.4008 1 0 0.6051
Total 246 322 227 229 86 49
E. Gowin et al. / International Journal of Infectious Diseases 43 (2016) 13–16 15Antiviral therapy led to the complete elimination of both
genotypes of HCV in 1/2 patients with HCV 1b+3a infection and in
1/3 patients with HCV 1b+4a infection. In the remaining patients,
treatment eliminated the genotype 3a and genotype 4a, and in
each case genotype 1b remained.
4. Discussion
The estimated prevalence of anti-HCV antibodies in the Polish
population ranges from 0.6% to 2.1%; thus, around 231 000 people
are infected. The observed high prevalence of HCV genotype 1 is in
accordance with the literature.1,6,7 In a study performed in 2013 by
Panasiuk et al., genotype 1 was detected in almost 80% of
patients.13 A similar prevalence of genotype 1 has been observed in
the Czech Republic and Hungary. HCV genotypes vary by ethnicity,
and in Poland the number of people of Asian or African origin is
very low. It was therefore not surprising that genotypes 5 and
6 were not detected, as all of the patients in the study group were
Caucasian.
The main source of HCV infection before 1992 was blood
products. This may explain the homogeneity of genotypes in the
Polish population and the predominance of genotype 1. The
transmission of HCV through medical procedures is now low. More
cases are connected to interventions such as tattooing and
cosmetic procedures. Adventure travel can cause the migration
of genotypes.
Genotype distribution varies with age. Genotype 3 is more
common in younger patients.1,6 In Europe, genotype 3a is
associated with intravenous drug use. In recent years the
frequency of genotype 3 infection has been decreasing, perhaps
as a result of the lower popularity of intravenous drugs and more
common use of disposable syringes and needles.12 In the present
study group, genotype 3a was more common among men, which
could be explained by the male predominance among intravenous
drug users.
Patients with chronic hepatitis C who qualiﬁed for treatment
were analyzed in this study. The total distribution of HCV
genotypes in the population may be different. HCV genotype is
not a prognostic factor for disease progression; however, it is
important for clinicians to know the genotypes in order for
treatment to be adjusted14. Subtype identiﬁcation has no clinical
impact on current therapy. However this may change with the
more common use of DAAs. Subtype identiﬁcation might become
necessary in the future when a greater number of treatment
choices are available.
Mixed genotype HCV infections are not very common in the
Polish population. In a study by Panasiuk et al., mixed genotypeinfections were diagnosed in 1.6% of patients.13 This is in
accordance with the results of other studies. Al Balwi, in a study
on 1292 patients with HCV, found mixed HCV genotypes in 1.7% of
patients, with genotype 4 being the most frequent genotype
encountered.15 Of 22 125 HCV-positive patients in Pakistan, 5.5%
had HCV mixed genotype infections and the most prevalent was
3a+3b.16 In Brazil, mixed HCV infections were detected in 7.1% of
former drug users.11 Women in Pakistan were found to have a
lower rate of mixed genotype infection compared to men.16 In
England, in a study performed on 38 040 patients, the frequency of
mixed genotypes was 0.2%.8 Data from Sweden and Russia have
shown no mixed genotype HCV infection.7
The risk factors for mixed genotype infections are blood
transfusions, the use of blood products, multiple uses of needles or
syringes, sharing razors, piercing instruments, nail clippers, and
toothbrushes, and major and minor dental surgery. Difﬁculties
assessing the true prevalence of mixed genotypes are prominent in
patients with multiple exposures. The rate of HCV mixed infection
depends on the prevalence of risk factors in the populations
studied.
When individuals are infected with more than one genotype,
changes in the predominant genotype over time can be observed.
The presence of different HCV variants in different tissues has been
observed and it is believed that there are extra-hepatic replication
sites. HCC and cirrhosis have been found to be more common
among patients with mixed HCV genotypes.
The patients with mixed genotypes in the present study
experienced a partial treatment response. The current treatment of
chronic hepatitis C in Poland is based on the combination of PEG-
IFN-a and RBV. This fails in 50–60% of patients with genotype
1 and in 20% of those with genotypes 2 and 3.17 HCV genotype is an
important predictor of the treatment response. Patients with
genotypes 2 and 3 have higher SVR rates than patients with
genotype 1. The development of new DAAs and the possibility of
different responses among the different genotypes makes HCV
genotyping and subtyping even more important.14
Presently, HCV genotyping plays a role in predicting the
achievement of a SVR to standard treatment and the selection of
the type and duration of treatment. A similar situation might be
observed for DAA treatment. It is already known that patients
infected with HCV genotypes 2 and 3 should be treated with PEG-
IFN-a and RBV for 24 weeks at lower doses compared with the
other genotypes, which require longer treatment.18 The purpose of
detecting the HCV genotypes is to help adjust treatment. The cost
of treatment with DAAs is relatively high, so the clinical application
of an expensive genotyping procedure may be justiﬁed for the
selection of candidates for treatment, for deciding the duration of
E. Gowin et al. / International Journal of Infectious Diseases 43 (2016) 13–1616treatment, and for predicting the response to treatment, risk of
resistance, and side effects.
The results obtained in this study showed that infection with
mixed HCV genotypes in Polish patients with chronic hepatitis C is
uncommon, as is the case in other countries. The selective
elimination of genotypes 3a and 4a after therapy conﬁrms the
greater resistance to currently used antiviral treatment of
genotype 1b. In the context of new anti-HCV drug development,
further investigations are needed to determine the clinical
importance of mixed HCV infection.
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